Market Overview

UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution

Related EXEL
Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress
Morning Market Gainers
Roche's metastatic melanoma combo cleared in Europe (Seeking Alpha)

Piper Jaffray reiterated its Neutral rating on Exelixis (NASDAQ: EXEL) and reduced its price target from $5.50 to $4.50.

Piper Jaffray said, "Exelixis raised net proceeds of $120 million by issuing 30 million shares at $4.25 and $250 million from a 4.25% convertible note bringing proforma cash to $665 million. Cabozantinib has a November 29th PDUFA date in medullary thyroid cancer (MTC). Both the COMET-1 and COMET-2 pivotal studies are underway in castrate resistant prostate cancer (CRPC) plus 11 investigator sponsored trials (ISTs) under a CRADA funded by the NCI. … We are trimming our price target to $4.50 from $5.50 to account for dilution from the deals."

Exelixis closed at $4.38 on Friday.

Latest Ratings for EXEL

Sep 2014Stifel NicolausDowngradesBuyHold
Sep 2014Cowen & CompanyDowngradesOutperformMarket Perform
Sep 2014Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings


Related Articles (EXEL)

View Comments and Join the Discussion!

Get Benzinga's Newsletters